Cargando…
1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales
BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776453/ http://dx.doi.org/10.1093/ofid/ofaa439.1412 |
_version_ | 1783630686962319360 |
---|---|
author | Ying, Yun Armstrong, Tom Blanchard, Laurine Kresken, Michael Zambardi, Gilles Pompilio, Marion |
author_facet | Ying, Yun Armstrong, Tom Blanchard, Laurine Kresken, Michael Zambardi, Gilles Pompilio, Marion |
author_sort | Ying, Yun |
collection | PubMed |
description | BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative treatment options, e.g. CRE and MDRO patients. The drug has bactericidal activity, it is active against organisms producing ESBL, Carbapenemase and aminoglycoside-modifying enzymes. The purpose of this study was to compare ETEST(®) PLZ bioMérieux to the broth microdilution reference method (BMD) for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and pneumoniae, Morganella morganii, Providencia stuartii, Proteus mirabilis and vulgaris and Serratia marcescens isolates. METHODS: A total of 598 isolates were tested by ETEST® (PLZ) and BMD at four clinical trial sites. Isolates were subcultured on tryptic soy or Columbia agar plates supplemented with 5% sheep blood. Suspensions of the isolates were prepared in 0.85% saline, which were used to inoculate BMD and Mueller Hinton agar for ETEST(®). Results were read after 16-20 hours incubation at 35°C +2°C in ambient air. QC organisms were tested with each run following CLSI QC guidelines. Results were analyzed using FDA breakpoints for PLZ (Susceptible <2 µg/mL, Intermediate 4 µg/mL, Resistant >8 µg/mL). Performance was evaluated using FDA performance criteria, EA and CA (≥ 90%), major error rate (≤3.0%) and very major error rate (≤2.0%). RESULTS: CONCLUSION: ETEST® PLZ clinical performance met the FDA acceptance criteria and was found useful for determining Plazomicin MIC of Enterobacterales, including ESBL, CRE (MBL, KPC, Oxa-48), high level AmpC and aminoglycoside resistant strains. Percent susceptibility of Plazomicin is at 80% among the 598 isolates tested, the mode MIC is 0.5 ug/ml as Susceptible. DISCLOSURES: Tom Armstrong, BS, bioMérieux (Employee) Laurine Blanchard, PhD, bioMérieux (Employee) Michael Kresken, PhD, bioMérieux (Scientific Research Study Investigator, Research Grant or Support) Gilles Zambardi, biomerieux (Employee) Marion Pompilio, BioMérieux (Employee) |
format | Online Article Text |
id | pubmed-7776453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77764532021-01-07 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales Ying, Yun Armstrong, Tom Blanchard, Laurine Kresken, Michael Zambardi, Gilles Pompilio, Marion Open Forum Infect Dis Poster Abstracts BACKGROUND: Plazomicin (PLZ) approved by FDA in June of 2018, is an aminoglycoside class antibacterial indicated for the treatment of adults with complicated urinary tract infections (cUTI) including pyelonephritis caused by Enterobacterales. It is used in patients who have limited or no alternative treatment options, e.g. CRE and MDRO patients. The drug has bactericidal activity, it is active against organisms producing ESBL, Carbapenemase and aminoglycoside-modifying enzymes. The purpose of this study was to compare ETEST(®) PLZ bioMérieux to the broth microdilution reference method (BMD) for Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca and pneumoniae, Morganella morganii, Providencia stuartii, Proteus mirabilis and vulgaris and Serratia marcescens isolates. METHODS: A total of 598 isolates were tested by ETEST® (PLZ) and BMD at four clinical trial sites. Isolates were subcultured on tryptic soy or Columbia agar plates supplemented with 5% sheep blood. Suspensions of the isolates were prepared in 0.85% saline, which were used to inoculate BMD and Mueller Hinton agar for ETEST(®). Results were read after 16-20 hours incubation at 35°C +2°C in ambient air. QC organisms were tested with each run following CLSI QC guidelines. Results were analyzed using FDA breakpoints for PLZ (Susceptible <2 µg/mL, Intermediate 4 µg/mL, Resistant >8 µg/mL). Performance was evaluated using FDA performance criteria, EA and CA (≥ 90%), major error rate (≤3.0%) and very major error rate (≤2.0%). RESULTS: CONCLUSION: ETEST® PLZ clinical performance met the FDA acceptance criteria and was found useful for determining Plazomicin MIC of Enterobacterales, including ESBL, CRE (MBL, KPC, Oxa-48), high level AmpC and aminoglycoside resistant strains. Percent susceptibility of Plazomicin is at 80% among the 598 isolates tested, the mode MIC is 0.5 ug/ml as Susceptible. DISCLOSURES: Tom Armstrong, BS, bioMérieux (Employee) Laurine Blanchard, PhD, bioMérieux (Employee) Michael Kresken, PhD, bioMérieux (Scientific Research Study Investigator, Research Grant or Support) Gilles Zambardi, biomerieux (Employee) Marion Pompilio, BioMérieux (Employee) Oxford University Press 2020-12-31 /pmc/articles/PMC7776453/ http://dx.doi.org/10.1093/ofid/ofaa439.1412 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Ying, Yun Armstrong, Tom Blanchard, Laurine Kresken, Michael Zambardi, Gilles Pompilio, Marion 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title | 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title_full | 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title_fullStr | 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title_full_unstemmed | 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title_short | 1227. Plazomicin Susceptibility Testing using ETEST(®) MIC for Enterobacterales |
title_sort | 1227. plazomicin susceptibility testing using etest(®) mic for enterobacterales |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776453/ http://dx.doi.org/10.1093/ofid/ofaa439.1412 |
work_keys_str_mv | AT yingyun 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales AT armstrongtom 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales AT blanchardlaurine 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales AT kreskenmichael 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales AT zambardigilles 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales AT pompiliomarion 1227plazomicinsusceptibilitytestingusingetestmicforenterobacterales |